Clinical Trial Update: Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19 [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating the efficacy of Tixagevimab/Cilgavimab and Regdanvimab for treating COVID-19 is listed with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infections

Drugs mentioned

• Regdanvimab (regdanvimab)
• Tixagevimab/Cilgavimab (tixagevimab and cilgavimab)

Snippet

Sponsor: City Clinical Hospital No.52 of Moscow Healthcare Department | Conditions: Coronavirus Infections | Phase 4 | Status: UNKNOWN